piperacillin + tazobactam + voriconazole

This is a combination therapy consisting of piperacillin, tazobactam, and voriconazole. Piperacillin is an extended-spectrum penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Tazobactam is a beta-lactamase inhibitor that protects piperacillin from enzymatic degradation by beta-lactamase-producing bacteria, thereby extending its antibacterial spectrum[3][5][10]. Voriconazole is a second-generation triazole antifungal agent that inhibits fungal ergosterol synthesis by blocking the enzyme lanosterol 14-alpha-demethylase (CYP51), disrupting fungal cell membrane formation and function[7][8]. This combination may be used in immunocompromised patients or those at high risk for both severe bacterial and invasive fungal infections, such as neutropenic cancer patients[1][9]. The drugs are administered intravenously.